Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spanish drug developer Almirall has introduced - Sativex a treatment for spasticity in multiple sclerosis (MS) in Germany.
Subscribe to our email newsletter
Additionally, Almirall has also received German approval for Actikerall as a treatment hyperkeratotic actinic keratosis (grade I/II) in adult patients.
Almirall is set to launch Actikerall in German market on 15 July 2011, as part of its plan to strengthen its presence in European market.
Almirall Germany, Austria and Switzerland managing director Farid Taha said Almirall aims to provide innovative solutions for patients.
"With the launch of Actikerall we will bring a new topical solution for non-melanoma skin cancer sufferers," Taha said.